PROGRAM OVERVIEW:

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

Type of Activity
Live Activity
Application

Educational Objectives

At the end of this activity, all participants should be able to:

• Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

NLA Opening Session-

Beyond Statins: Evolving Therapeutic Options for Dyslipidemia Management

• Describe the mechanisms of action of various non-statin therapies in managing several types of dyslipidemias.
• Apply evidence-based decision-making to select appropriate therapies beyond statins for patients with dyslipidemias, considering patient-specific factors such as LDL-C targets, comorbidities, and treatment tolerability.
• Evaluate the potential for integrating emerging therapies into clinical practice to optimize lipid management and reduce cardiovascular risk in statin-intolerant or high-risk patients.
• Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

Session II- Lipoproteins and Apoproteins: Structure to Function

• Recognize the role of apolipoprotein B (Apo B) as a universal target for ASCVD prevention 
• Review the role of novel therapeutic targets including ApoC-3 and its implications for patient treatment
• Examine the structure and function of Lp(a) and its use in cardiovascular risk assessment 

W. Virgil Brown Distinguished Achievement Award and Lectureship

• Evaluate the management of patients with dyslipidemia

Session III- Late Breakers

Session IV- Incretin mimetics in Lipid and Cardiometabolic Clinics

• Review therapeutic considerations for the use of incretin mimetics including GLP-1RA in patients with or at risk for ASCVD
• Outline the clinical benefits for implementing therapeutic lifestyle changes and dietary changes in patients treated with GLP-1 therapies

Session V- NLA/EAS Joint session 2025

• Explore LDL-C reduction as a primary target in lipid management, with an emphasis on early intervention and sustained control to reduce cardiovascular risk.
• Review remnant cholesterol and triglycerides, their implications for cardiovascular health, and current therapeutic strategies.
• Discuss the significance of Lp(a) as a cardiovascular risk factor, current and emerging treatments, and patient implications for Lp(a)-targeted therapies.
• Focus on integrated care models and systems approaches for lipid management, including examples of successful implementation of system approaches to lipid management, providing insights into models used in both the United States and Europe. Discuss how health data can be effectively used to identify and manage patients with high lipid levels, addressing population-level health data strategies.

Session VI- NLA Publications

• Describe current science and recommendations of importance to the practice of clinical lipidology

Session VII- Risk Stratification

• Discuss evidence regarding the utility of HDL as a target for ASCVD risk modification 
• Explore the use of CCTA in assessing patient risk 
• Discuss strategies for managing non-lipid risk factors for dyslipidemia including hypertension

Session VIII – Lifestyle and Nutrition

• Analyze the therapeutic benefits of an optimal diet including cumulative effects of macronutrients throughout the lifetime

• Review impacts of various dietary patterns on cardiometabolic health

Session IX – Severe Hypercholesterolemia

• Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for patients with FH 
• Explore the causes and prevalence of severe familial hypercholesterolemia (FH)
• Recognize the mechanisms driving the Lipid Energy Model and Lean Mass Hyper-responders (LMHR) models and their use in clinical practice. 

Session X- Abstract Award Winners

Session XI- Young investigator award winners

• Critically appraise emerging research and its applications to daily clinical practice

Session XII- Hypertriglyceridemia

• Recognize primary and secondary causes of hypertriglyceridemia and the role of various therapies used in treatment
• Review the role of novel therapeutic targets including AngPLT3-4 and its implications for patient treatment

Session XIII- LSP Case Presentations

• Discuss strategies for the management of patients with lipid disorders using a case-based approach

 

 

 

 

2025 SCIENTIFIC SESSIONS:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18.5 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 18.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 18.5 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

Pharmacist Accreditation Statement

Universal Activity Number Application JA0007192-0000-25-014-L01-P (Application)

This Activity has been approved for 18.5 contact hour(s) (1.85 CEUs) of the Accreditation Council for Pharmacy Education

Nursing

The maximum number of hours awarded for this CE activity is 18.5 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

 

Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
 

For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
For Dietitians: Upon completion of the activity evaluation form, dietitians may submit evaluations of the quality of activities/materials to CDR. Poor evaluations of activities/materials may trigger an audit of the activities / materials by CDR.

 

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

 

Commercial Support:
Full notification of commercial support will be provided in the activity materials.